Bionic cell membrane nanoparticle as well as preparation method and application thereof

A cell membrane and nanoparticle technology, applied in the field of pharmaceutical preparations, can solve the problems of "cold" tumors, tumors evading immune system monitoring, etc., and achieve the effects of high production cost performance, powerful anti-tumor, and simple preparation method.

Active Publication Date: 2021-06-18
CHINA PHARM UNIV
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, silencing of the STING signaling pathway by immune cells causes tumors to

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bionic cell membrane nanoparticle as well as preparation method and application thereof
  • Bionic cell membrane nanoparticle as well as preparation method and application thereof
  • Bionic cell membrane nanoparticle as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Preparation of biomimetic cell membrane nanoparticles (CMM-DiR):

[0044] (1) Accurately weigh 4.6mg Na 2 S 2 o 3 Dissolved in 5mL water, 3.9mg KMnO 4 Dissolve in 5mL of water.

[0045] (2) Na in step (1) 2 S 2 o 3 Aqueous solution was added to KMnO 4 In the aqueous solution, the mixed solution was placed in a 50mL double-necked flask, nitrogen gas was introduced, and stirred on a magnetic stirrer for 45 minutes to initially obtain black MnO 2 precipitation.

[0046] (3) Rinse the black precipitate obtained in step (2) with purified water at 60°C, and then dry at 110°C for 1.5 hours to obtain MnO 2 nanoparticles.

[0047] (4) B16-F10 mouse melanoma cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. When the confluence of the cells reached 80-90%, the cells were collected into the PBS solution by scraping, centrifuged at 700g for 7 minutes, and then resuspended in a 50:50 solution of cryopreservation med...

Embodiment 2

[0058] Preparation of biomimetic cell membrane nanoparticles (CMM-DiR):

[0059] (1) Accurately weigh 9mg Na 2 S 2 o 3 Dissolved in 10mL water, 7.5mg KMnO 4 Dissolve in 10mL of water.

[0060] (2) Na in step (1) 2 S 2 o 3 Aqueous solution was added to KMnO 4 In the aqueous solution, the mixed solution was placed in a 50mL double-necked flask, nitrogen gas was introduced, and stirred on a magnetic stirrer for 45 minutes to initially obtain black MnO 2 precipitation.

[0061] (3) Rinse the black precipitate obtained in step (2) with purified water at 60°C, and then dry at 110°C for 2 hours to obtain MnO 2 nanoparticles.

[0062] (4) B16-F10 mouse melanoma cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. When the confluence of the cells reached 80-90%, the cells were collected into the PBS solution by scraping, centrifuged at 700g for 7 minutes, and then resuspended in a 50:50 solution of cryopreservation mediu...

Embodiment 3

[0068] Preparation of biomimetic cell membrane nanoparticles (CMM-DiR):

[0069] (1) Accurately weigh 5.2mg Na 2 S 2 o 3 Dissolved in 5mL water, 4.8mg KMnO 4 Dissolve in 5mL of water.

[0070] (2) Na in step (1) 2 S 2 o 3 Aqueous solution was added to KMnO 4 In the aqueous solution, the mixed solution was placed in a 50mL double-necked flask, nitrogen gas was introduced, and stirred on a magnetic stirrer for 60 minutes to initially obtain black MnO 2 precipitation.

[0071] (3) Rinse the black precipitate obtained in step (2) with purified water at 60°C, and then dry at 110°C for 2 hours to obtain MnO 2 nanoparticles.

[0072] (4) B16-F10 mouse melanoma cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. When the confluence of the cells reached 80-90%, the cells were collected into the PBS solution by scraping, centrifuged at 700g for 7 minutes, and then resuspended in a 50:50 solution of cryopreservation medium ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a bionic cell membrane nanoparticle as well as a preparation method and application thereof. The bionic cell membrane nanoparticle comprises a tumor cell membrane vesicle and a chemotherapeutic drug, wherein the chemotherapeutic drug is encapsulated in the tumor cell membrane vesicle, and a photothermal agent or a photosensitizer is loaded in the tumor cell membrane vesicle. An STING activator encapsulated in the bionic cell membrane nanoparticle can activate an STING pathway in an antigen-presenting cell (APCs); meanwhile, a preparation is taken by tumor cells through the homologous adhesion characteristic of a tumor cell membrane, and the photothermal agent generates high temperature or the photosensitizer generates singlet oxygen (ROS) under the irradiation of exogenous laser so as to promote the release of tumor-associated antigens, so that primary tumors are converted into therapeutic STING activated vaccines. The therapeutic STING vaccines can generate a strong anti-tumor effect in malignant tumors.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a bionic cell membrane nanoparticle for treating malignant tumors by immunotherapy, a preparation method and application thereof. Background technique [0002] Cancer caused by malignant tumors is a major killer threatening human health in the world today. Conventional cancer treatment methods (surgery, radiotherapy, chemotherapy, etc.) have relatively high toxicity and side effects, are poor in selectivity, are prone to drug resistance, and are increasingly unable to meet the needs of clinical treatment. Tumor immunotherapy is highly specific and has the advantages of durable response and long-term survival. Immunotherapy has revolutionized traditional tumor treatment methods and achieved unprecedented clinical efficacy. [0003] As an emerging research field, cancer vaccines can effectively prevent cancer. However, due to the heterogeneity wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/46A61K41/00A61K33/32A61P35/00A61P35/04C12N5/09
CPCA61K9/5176A61K41/0052A61K41/0057A61K41/0061A61K41/0071A61K33/32A61P35/00A61P35/04C12N5/0693C12N2509/00A61K2300/00
Inventor 孙敏捷杨学王铮
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap